Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route
Virology · 2026
DOI: 10.1016/j.virol.2026.111007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Virology, 2026. Verfasst von Ahmedali S Mandviwala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Virology, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to Be University), Pune, Ind…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Vaccines, Virus-Like Particle, Respiratory Syncytial Virus Infections, Adjuvants, Immunologic. Die Arbeit nennt 65 Literaturangaben. Gefördert von: Bharati Vidyapeeth.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease in infants and older adults, and despite recent advances in prefusion F-based vaccines and monoclonal antibody prophylaxis, additional vaccine strategies remain of interest. Virus-like particle (VLP) platforms offer a promising approach by mimicking the native virion structure while maintaining an excellent safety profile. In this study, we evaluated the immunogenicity and protective efficacy of RSV-VLPs containing prefusogenic F, G and matrix (M) proteins, administered intramuscularly with or without adjuvants targeting pattern-recognition receptors (MPLA, CL413 and CL429). Immunization of mice with adjuvanted RSV-VLPs induced robust systemic IgG responses, enhanced binding to RSV-F and G proteins and significantly higher neutralizing antibody titers compared to unadjuvanted VLPs and alum-adjuvanted FI-RSV controls. Analysis of IgG subclasses indicated a balanced or Th1-skewed antibody response. Splenocyte cytokine profiling revealed elevated IFN-γ, TNF, IL-2 and IL-6 secretion in groups receiving MPLA- or CL429-adjuvanted formulations, while IL-4 remained low, confirming Th1 dominance. Notably, CL413 promoted detectable IL-17 A production, indicative of Th17 activation. Upon viral challenge, all adjuvanted VLP formulations conferred effective protection against RSV-induced pulmonary inflammation, with markedly reduced lung pathology scores. Collectively, these results demonstrate that chimeric TLR-based adjuvants performed equally or better than MPLA in certain cases and enhance the quality but not magnitude of immune responses to RSV-VLPs delivered intramuscularly. These findings underscore the translational potential of adjuvanted VLP vaccines for safe and effective parenteral RSV immunization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Virology, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to Be University), Pune, India.
- Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Translational Virology, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to Be University), Pune, India. Electronic address: harshad.patil@bharatividyapeeth.edu.
Förderung
- Bharati Vidyapeeth
Zitieren
APA
Mandviwala, A. S., Liman, K., Huckriede, A. L. W., Mishra, A. C., & Patil, H. P. (2026). Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route. Virology. https://doi.org/10.1016/j.virol.2026.111007
Vancouver
Mandviwala AS, Liman K, Huckriede ALW, Mishra AC, Patil HP. Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route. Virology. 2026. doi:10.1016/j.virol.2026.111007
BibTeX
@article{Mandviwala2026,
author = {Mandviwala, Ahmedali S and Liman, Komal and Huckriede, Anke L W and Mishra, Akhilesh Chandra and Patil, Harshad P},
title = {Evaluation of MPLA and chimeric TLR agonist adjuvants in RSV virus-like particle vaccines delivered by the intramuscular route},
journal = {Virology},
year = {2026},
doi = {10.1016/j.virol.2026.111007}
}
EUVIMED